EM1809G "Hemophilia: Past, Present, and Future"

Hemophilia A and B are rare X-linked recessive bleeding disorders. Prior to the availability of safe and effective clotting factor concentrates, hemophilia resulted in early mortality from catastrophic bleeding and poor quality of life due to hemophilic arthropathy. The goal of this program is to describe the advances in hemophilia management over the last 50 years, and discuss novel therapies that are easing the burden on patients and paving the way for a possible cure in the future.

Download Protocol

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Understand why hemophilia A and B lead to a bleeding diathesis.
  • Understand the concept of prophylaxis and how this has changed the natural history of severe hemophilia.
  • Describe strategies for managing inhibitor development.
  • Explain the rationale behind novel therapies targeting natural anticoagulants.
  • Describe the progress made in gene therapy that may eventually lead to a life-long cure.
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
10/03/2018
Course expires: 
11/02/2018
Cost:
$0.00
Rating: 
0

Photo: Catherine Chen, M.D. Siayareh Rambally, M.D.
Assistant Professor of Internal Medicine
Division of Hematology/Oncology

Available Credit

  • 1.00 AMA

Accreditation Period

Course opens: 
10/03/2018
Course expires: 
11/02/2018

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome